/
IMRX
$5.05+$0.29 (+6.09%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$308.0M
65M shares
52-week range
$2.90 – $10.08
30% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
4.11%
Moderate
Price (6 mo)
Loading chart…
Change$-12.54
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.9M | $2.3M | $2.1M | $317.0K | $0 | $0 | $0 |
| Cost of revenue | $1.2M | $1.3M | $1.2M | $158.1K | $0 | $0 | $698.9K |
| Gross profit | $696.7K | $1.0M | $926.9K | $158.8K | $0 | $0 | −$698.9K |
| Gross margin | 36.3% | 44.6% | 44.6% | 50.1% | — | — | — |
| R&D | $4.3M | $15.0M | $26.5M | $36.3M | $41.6M | $48.0M | $42.0M |
| Operating income | −$6.3M | −$17.1M | −$33.9M | −$51.7M | −$58.4M | −$64.1M | −$59.4M |
| EBITDA | −$7.3M | −$17.0M | −$33.7M | −$51.5M | −$58.1M | −$63.7M | −$55.3M |
| Net income | −$7.7M | −$17.0M | −$33.5M | −$50.5M | −$53.5M | −$61.0M | −$56.0M |
| Net margin | -401.6% | -737.2% | -1612.3% | -15937.3% | — | — | — |
| EPS (diluted) | -0.60 | -1.26 | -1.27 | -1.87 | -1.88 | -2.04 | -1.27 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-1.14 | $-1.23–$-0.96 | 5 |
| 2027 | $16M | $-1.34 | $-1.55–$-1.12 | 4 |
| 2028 | $52M | $-1.25 | $-2.13–$0.31 | 5 |
| 2029 | $97M | $-0.77 | $-0.77–$-0.77 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.80
Price
$5.05
Implied downside
-44%
Peer comparison
Immuneering Corporation Class A Common Stock
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
www.immuneering.com- Employees
- 55
- IPO / List date
- Jul 30, 2021
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds IMRX.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 72,875 | $384.1K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IMRX yet.
